ArticleJACC. Basic to translational science2021
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension.
Article in JACC. Basic to translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01960946 (Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.Circulation · 2022Pooled it
- Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Trial
- Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants.Cancer chemotherapy and pharmacology · 2023Trial
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Galectin-3 and the Glyco-Inflammatory Axis: A Missing Link to Residual Cardiovascular Risk in Coronary Artery Disease.Biomedicines · 2025Review
- Pleiotropic regulatory mechanisms and targeted therapeutic prospects of Galectin-3 in aging-related diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- High Levels of Galectin-3 and Uric Acid Are Independent Predictors of Renal Impairment in Patients with Stable Coronary Artery Disease.Journal of clinical medicine · 2025Article
- Galectin-3 in Cardiovascular Health: A Narrative Review Based on Life's Essential 8 and Life's Simple 7 Frameworks.Current issues in molecular biology · 2025Review
- Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis.Journal of materials chemistry. B · 2025Article
- Oxidative stress in diabetes mellitus and its complications: From pathophysiology to therapeutic strategies.Chinese medical journal · 2025Review
- Galectins-1, -3 and -9 in leukemia: mechanistic insights and therapeutic translation.Frontiers in immunology · 2025Review
- The Possible Effects of Galectin-3 on Mechanisms of Renal and Hepatocellular Injury Induced by Intravascular Hemolysis.International journal of molecular sciences · 2024Review
- Using Omics to Identify Novel Therapeutic Targets in Heart Failure.Circulation. Genomic and precision medicine · 2024Review
- Sex Differences in Circulating Biomarkers of Heart Failure.Current heart failure reports · 2024Review
- Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure.JACC. CardioOncology · 2023Article
- Unveiling Plant-Based Pectins: Exploring the Interplay of Direct Effects, Fermentation, and Technological Applications in Clinical Research with a Focus on the Chemical Structure.Plants (Basel, Switzerland) · 2023Review
- Resveratrol supplementation: a therapeutic potential for cardiac remodeling in hypertensive heart disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.Biomolecules · 2023Review
- Targeting galectin-driven regulatory circuits in cancer and fibrosis.Nature reviews. Drug discovery · 2023Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.